SEOUL -- Samsung BioLogics has become the world's largest contract manufacturer of biopharmaceuticals by output capacity, the company said, with the recent completion of its third plant.
The company invested 850 billion won ($759 million) to build the new plant, located in Incheon on the outskirts of Seoul, doubling its total production capacity to 360,000 liters a year and putting it ahead of Switzerland's Lonza and Germany's Boehringer Ingelheim.
